Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Acne Infection01:27

Acne Infection

Acne is a multifactorial skin condition primarily affecting adolescents and young adults, with a global prevalence estimated to exceed 75% in this demographic. The condition is characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, nodules, and, in severe cases, cysts, particularly in areas rich in sebaceous glands such as the face, neck, chest, and back. The pathogenesis involves increased sebum production, follicular hyperkeratinization, colonization by...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pityriasis rubra pilaris.

Journal of the American Academy of Dermatology·2024
Same author

Letter from the Editor: Understanding Confidence Intervals and the Limitations of Statistics.

Journal of the American Academy of Dermatology·2024
Same author

Letter from the editor: Parametric and nonparametric tests.

Journal of the American Academy of Dermatology·2024
Same author

Letter from the editor: Chi square.

Journal of the American Academy of Dermatology·2024
Same author

Letter from the Editor: The null hypothesis.

Journal of the American Academy of Dermatology·2024
Same author

Cutaneous sarcoidosis treated with intralesional adalimumab.

International journal of dermatology·2024

Related Experiment Video

Updated: Jun 11, 2026

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles
09:57

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

IL-1-targeted therapy in dermatologic conditions.

Kerem Balan1, Dirk M Elston2

  • 1Department of Dermatology & Dermatologic Surgery, Medical University of South Carolina, Charleston, South Carolina; Department of Dermatology and Venereology, Etimesgut Sehit Sait Erturk State Hospital, Ankara, Turkiye.

Journal of the American Academy of Dermatology
|June 9, 2026
PubMed
Summary
This summary is machine-generated.

Interleukin-1 (IL-1) blockade effectively treats specific autoinflammatory and neutrophilic skin diseases. However, its efficacy varies across conditions, necessitating careful patient selection and phenotyping for optimal outcomes in IL-1-driven disorders.

Keywords:
autoinflammatory diseasesbiological therapyhidradenitis suppurativainterleukin-1neutrophilic dermatoses

Related Experiment Videos

Last Updated: Jun 11, 2026

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles
09:57

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

Area of Science:

  • Dermatology
  • Immunology
  • Genetics

Background:

  • Interleukin-1 (IL-1) is crucial in inflammasome activation, keratinocyte signaling, and neutrophil recruitment.
  • IL-1 drives numerous neutrophil-rich and suppurative dermatoses.
  • IL-1 blockade shows promise for various inflammatory skin conditions.

Purpose of the Study:

  • To review the efficacy of IL-1 blockade in IL-1-driven autoinflammatory and neutrophilic dermatoses.
  • To summarize practical considerations for using IL-1 antagonists.
  • To highlight the importance of clinical and genetic phenotyping.

Main Methods:

  • Literature review of cohort and case series data.
  • Analysis of evidence for IL-1 blockade in various dermatological conditions.
  • Summary of clinical considerations, dosing, and safety.

Main Results:

  • Robust evidence supports IL-1 blockade for cryopyrin-associated periodic syndromes, monogenic periodic fever syndromes, and Schnitzler syndrome.
  • High efficacy demonstrated in IL-1 receptor antagonist deficiency and pyoderma gangrenosum.
  • Variable efficacy observed in hidradenitis suppurativa, pustular psoriasis, and PSTPIP1-associated autoinflammatory diseases.
  • Limited evidence for IL-36 receptor antagonist deficiency, SAPHO, Sweet, and VEXAS syndromes.

Conclusions:

  • IL-1 antagonists are essential for specific IL-1-driven disorders.
  • IL-1 blockade is a rational rescue therapy for selected neutrophilic dermatoses.
  • Careful phenotyping is vital for guiding IL-1 antagonist therapy.